[ad_1]
SALT LAKE CITY, Feb. 15, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today its support for the new American Society of Breast Surgeons guidelines. (ASBrS) which recommends that all people diagnosed with bad cancer undergo genetic testing with a multi-gene panel.
"We congratulate ASBrS for recognizing the important scientific advances and for recommending genetic testing for all people with bad cancer," said Johnathan Lancaster, MD, Ph.D. , Chief Medical Officer, Myriad Genetics. "The valuable information provided by genetic testing improves the ability of physicians to select appropriate precision treatments, personalize care for patients and their families, and improve health outcomes."
These new ASBrS guidelines are based on a recently published research by the Breast Care Network for Targeted Medical Education (TME) in the Journal of Clinical Oncology. The study showed that patients meeting the National Comprehensive Cancer Network's (NCCN) existing clinical test criteria had similar rates of pathogenic / probable hereditary mutations in bad cancer genes (9%) compared to patients not meeting the NCCN criteria (8%).
"I am excited about our new ASBrS guidelines and look forward to the day the NCCN will also update its guidelines. Interesting new evidence has shown that about half of bad cancer patients have clinically exploitable mutations that are omitted when genetic testing is limited to patients meeting current NCCN guidelines, "said Walton Taylor, MD. , president of ASBrS. In his letter to the members, he warned that "as genetic tests develop, it is important to carefully select the laboratory ensuring that it provides quality tests with accurate results and a high level of accuracy. appropriate follow-up ".
Myriad Genetics has been a leader in hereditary cancer screening for over two decades and Myriad's MyRisk® The hereditary cancer test is the market-leading test for patients trying to understand their hereditary cancer risk. According to the American Cancer Society, 330,000 people are diagnosed each year with bad cancer in the United States, and about 10% of them are caused by inherited mutations. Less than 10% of BRCA1 / 2 carriers have been identified and up to 80% of those at risk have not been tested for genetic testing because they do not meet the family history criteria of current testing guidelines. The National Cancer Institute estimates that 35,000 bad cancer patients have pathogens. BRCA1 / 2 mutations, but only 30% have been identified. In addition, it is estimated that 10 to 15% of women who test negative BRCA1 / 2 the mutations have pathogenic variants of other cancer susceptibility genes, including: ATM, CDH1, CHEK2, NBN, NF1, PALB2, TP53, STK11 and PTEN.
"Knowing, it's power and the new ASBrS guidelines send a strong message to the bad cancer community: Genetic testing is appropriate for all people diagnosed with bad cancer," said Stacey Tinianov, Survivor Consultant. bad cancer and advocacy and advocacy in Santa Clara, California. "I am optimistic that the NCCN will review the evidence and update its bad cancer guidelines so that appropriate genetic testing becomes the standard of care and is widely available."
Sure Myriad myRisk® Hereditary cancer
The Myriad MyRisk Hereditary Cancer Test utilizes a large number of sophisticated technologies and proprietary algorithms to evaluate 29 clinically significant genes badociated with eight inherited cancer sites, including: bad, colon, ovarian cancers, of the endometrium, pancreas, prostate and stomach, and melanoma.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming the lives of patients around the world with innovative molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing a disease, accurately diagnose the disease, badess the risk of disease progression, and guide treatment decisions in six major medical specialties where molecular diagnosis can significantly improve patient care and reduce health care costs. Myriad focuses on five strategic imperatives: supporting a solid foundation of hereditary cancer, increasing the volume of new products, expanding reimbursement coverage for new products, increasing revenue from RNA kits and improving profitability with Elevate 2020. To learn more about Myriad's impact on the difference, visit the company's website: www.myriad.com. Follow Myriad on Twitter via @MyriadGenetics.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, BRACAnalysis CDx Tumor, myChoice HRD, EndoPredict, Vectra, GeneSight, RiskScore Prolaris, Fores and Prechem Genetics, Inc. or its affiliates at 100% in the United States and in other countries. MYGN-F, MYGN-G.
Declaration of the Safe Harbor
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the recommendation of the American Society of Breast Surgeons (ASBrS) regarding new guidelines applicable to all people with bad cancer genetic test with a multi-gene panel; the value of information provided by genetic testing to strengthen the ability of physicians to select precision treatments, to personalize the care provided to patients and their families, and to improve health outcomes; the opportunity and timeliness of the NCCN to update its guidelines in accordance with the new ASBrS guidelines; and the company's strategic guidelines under the caption "About Myriad Genetics". These "forward-looking statements" are based on management's current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual and actual results to differ materially and adversely from those expressed in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk of decreased sales and profit margins of our molecular diagnostic tests and our pharmaceutical and clinical services; the risks badociated with our ability to move from our existing product portfolio to our new tests, including unplanned costs and delays; risks related to decisions or changes in the reimbursement levels of government or private insurers for our tests or our ability to obtain the reimbursement of our new tests at levels comparable to those of our existing tests; the risks of increased competition and the development of new competing tests and services; the risk that we will not be able to develop or obtain commercial success for timely molecular diagnostic tests and additional pharmaceutical and clinical services, if at all; the risk that we will not be able to successfully develop new markets for our molecular diagnostic tests and our pharmaceutical and clinical services, including our ability to generate revenue outside the United States; the risk that licenses for the technology underlying our molecular diagnostic tests and our pharmaceutical and clinical services and all future tests and services will be terminated or can not be maintained under satisfactory conditions; the risks of delays or other problems related to the operation of our laboratory testing facilities and our health care clinic; risks related to public concerns about genetic testing in general or our testing in particular; risks related to regulatory requirements or their application in the United States and in foreign countries and changes in the structure of the health system or health care payment systems; the risks badociated with our ability to obtain new business collaborations or licenses and to acquire new technologies or new businesses on satisfactory terms, if at all; the risks badociated with our ability to successfully integrate and leverage technologies or businesses that we license or acquire; risks related to our forecasts of our business, results of operations and financial condition; risks related to potential market opportunities for our products and services; the risk that we or our licensors may not be able to protect or that third parties are infringing proprietary technologies that underlie our testing; the risk of claims for patent infringement or of the validity of our patents or any other intellectual property; the risks badociated with changes in intellectual property law relating to our molecular diagnostic tests and our pharmaceutical and clinical services and our patents or their enforcement in the US and in foreign countries, such as the Court's decision Supreme in the case brought against us by the Association for Molecular Pathology et al; the risks of new, changing and competitive technologies and regulations in the United States and around the world; the risk that we may not be able to comply with the covenants of financial exploitation under our credit or loan agreements; the risk that we will not be able to pay, upon maturity, amounts due under our credit or loan agreements; and other factors described under "Risk Factors" in Item 1A of our most recent Annual Report on Form 10-K for the year ended June 30, 2018, filed with the Securities and Exchange Commission, and any updates to these risk factors that are reported from time to time in our quarterly reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is valid as of the date of publication of the press release. Myriad has no obligation to update this information, except as required by law.
Source link
